Clinical trials: Body Weight Control
Type 2 Diabetes Mellitus, Obese
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
- Trial name
- NCT01918865
- Testing
- ISIS-PTP1BRx, daily OAD (metformin and/or sulfonylurea)
- Where
- 21 sites in Argentina, Canada and 1 more
- Volunteers
- 92 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Overweight , Obesity
Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 Injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07804810
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Energy Expenditure
Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.
The study is considered research because efficacy (how well a drug works) information is needed in healthy, 25-45 year-old, female subjects with moderate caffeine intake.
- Trial name
- NCT00781586
- Testing
- One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350), Caffeine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Overweight, Obesity
Benefit and Tolerability of IQP-LU-104 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-LU-104 (5120mg and 2560mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03888911
- Testing
- High dose IQP-LU-104 (5120mg), Low dose IQP-LU-104 (2560mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity and Type 2 Diabetes
BMS-646256 in Obese and Overweight Type 2 Diabetics
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2…
- Trial name
- NCT00541567
- Testing
- ibipinabant
- Volunteers
- 600 people
- Sponsor
- Solvay Pharmaceuticals
Metabolic Syndrome, Dyslipidemia
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
The purpose of this study is to investigate if daily consumption of barley beta-glucans effect lipid and glucose metabolism and alter intestinal microbiota composition in participants with metabolic syndrome or with high risk for…
- Conditions
- Metabolic Syndrome, Dyslipidemia, Obesity, Abdominal, Hyperglycemia
- Trial name
- NCT02041104
- Testing
- Bread with added beta-glucans
- Where
- 3 sites in Slovenia
- Volunteers
- 51 people
- Sponsor
- Mlinotest Zivilska Industrija d.d.
Diabetes, Diabetes Mellitus, Type 1
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes
This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542463
- Testing
- insulin detemir
- Where
- Germany
- Volunteers
- 4,464 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers
The purpose of this study is to evaluate the safety and tolerance of single intravenous (through a vein) doses of trodusquemine. Different amounts of trodusquemine will be given to each volunteer group throughout the study.
- Trial name
- NCT00509132
- Testing
- trodusquemine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Genaera Corporation
Obesity
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
- Trial name
- NCT06277934
- Testing
- RGT001-075
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Regor Pharmaceuticals Inc.
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
This study investigates the effectiveness and safety of 12 weeks of treatment with JNJ-16269110 (R256918), in overweight and obese patients.
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00622765
- Testing
- R256918
- Where
- 18 sites in Belgium, Denmark and 5 more
- Volunteers
- 321 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are…
- Trial name
- MARITIME-OSA-2 (NCT07226765)
- Testing
- Maridebart cafraglutide
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Obesity, Overweight
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05110846
- Testing
- CT-868
- Where
- 5 sites in Mexico
- Volunteers
- 103 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity or Overweight
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-3 (NCT07843498)
- Testing
- Petrelintide
- Where
- 3 sites in United States
- Volunteers
- 3,900 people
- Sponsor
- Hoffmann-La Roche
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Obesity
Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers
The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well tolerated in obese female subjects. The study will also provide information on how much ZGN-433 gets into the blood, how long does it stay…
- Trial name
- NCT01028261
- Testing
- ZGN-433
- Where
- 2 sites in Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Obesity
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days.
- Trial name
- NCT04447261
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Hypertension With Overweight or Obesity
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
- Trial name
- NCT07528027
- Testing
- HRS-7535
- Where
- 2 sites in China
- Volunteers
- 648 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers.
- Trial name
- NCT06804603
- Testing
- Tradipitant
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Vanda Pharmaceuticals
Overweight or Obesity
A Study of ZT002 Injection in Participants With Overweight or Obesity
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.
- Trial name
- NCT06371326
- Testing
- ZT002 Injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
- Trial name
- KaiNETIC-3 (NCT07284979)
- Testing
- Ribupatide, Semaglutide
- Where
- 60 sites in United States, Australia and 3 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera